For the Inventor, By the Inventor

Enter assignee name

Lebanon, NH, United States of America

Adimab, LLC

USPTO Granted Patents = 48

CIPO Patents = 16

EPO Patents = 11

Trademarks = 8

Forward Citations = 162

Loading Chart...

Loading Chart...

70 inventors (with patents filed for the assignee):

Laura M Walker (16 out of 23 patents)

Michael Feldhaus (13 out of 29 patents)

Maximiliano Vasquez (12 out of 68 patents)

4. Bianka Prinz (9 out of 58 patents)

5. Zhu Chen (8 out of 8 patents)

6. Kenneth Ellsworth (8 out of 9 patents)

7. James Milligan (8 out of 8 patents)

8. Elizabeth Oldham (8 out of 8 patents)

9. Dietmar Seiffert (8 out of 8 patents)

10. Zachary A Bornholdt (7 out of 7 patents)

11. Larry Zeitlin (7 out of 7 patents)

12. Kartik Chandran (7 out of 20 patents)

13. Eric Krauland (7 out of 20 patents)

14. Anna Z Wec (7 out of 14 patents)

15. K Dane Wittrup (7 out of 27 patents)

48 patents: Sort by Forward Citations

1. 12281156 - Anti-respiratory syncytial virus antibodies, and methods of their generation and use (2025-04-21),

2. 12275800 - Anti-coagulation factor XI antibodies (2025-04-14),

3. 12258679 - Polyclonal mixtures of antibodies, and methods of making and using them (2025-03-25),

4. 12215141 - Anti-respiratory syncytial virus antibodies, and methods of their generation and use (2025-02-04),

5. 12209117 - Monoclonal antibodies and cocktails for treatment of Ebola infections (2025-01-28),

6. 12181480 - Polyspecificity reagents, methods for their preparation and use (2024-12-31),

7. 12180299 - Multispecific antibody analogs comprising a common light chain, and methods of their preparation and use (2024-12-31),

8. 12018403 - Antibody libraries (2024-06-25),

9. 11746160 - Antibodies against BACE1 and use thereof for neural disease immunotherapy (2023-09-05),

10. 11661460 - Anti-coagulation factor XI antibodies (2023-05-30),

11. 11542330 - Anti-CD3-binding domains and antibodies comprising them, and methods for their generation and use (2023-01-03),

12. 11512142 - Anti-coagulation factor XI antibodies (2022-11-29),

13. 11485794 - Anti-coagulation factor XI antibodies (2022-11-01),

14. 11485775 - Anti-respiratory syncytial virus antibodies, and methods of their generation and use (2022-11-01),

15. 11479615 - Anti-coagulation factor XI antibodies (2022-10-25),

Adimab is a privately held biotechnology company focused on developing fully human monoclonal antibodies. The company has developed a proprietary yeast-based antibody discovery platform that enables rapid and efficient generation of therapeutic antibodies for a wide range of diseases. Adimab's technology has been utilized to discover and optimize antibody candidates for various partners in the pharmaceutical and biotech industry.

This text is generated by artificial intelligence and may not be accurate.

Company Badge

USPTO Data Jan 1 1976 - Dec 9 2025

48 Patents

#3 in Lebanon, NH

#51 in New Hampshire

#7,024 in US

#14,104 in the World

Lebanon, NH, United States of America

Adimab, LLC

Forward Citations = 162

70 inventors:

Laura M Walker (16 out of 23 patents)

Michael Feldhaus (13 out of 29 patents)

Maximiliano Vasquez (12 out of 68 patents)

4. Bianka Prinz (9 out of 58 patents)

5. Zhu Chen (8 out of 8 patents)

Please report any incorrect information to support@idiyas.com

Loading…